The Current State of Coronary Revascularization: Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Interventions.

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
ACS Applied Electronic Materials Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI:10.1007/s11886-024-02090-x
Chayakrit Krittanawong, Affan Rizwan, Muzamil Khawaja, Noah Newman, Johao Escobar, Hafeez Ul Hassan Virk, Mahboob Alam, Fu'ad Al-Azzam, Celina M Yong, Hani Jneid
{"title":"The Current State of Coronary Revascularization: Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Interventions.","authors":"Chayakrit Krittanawong, Affan Rizwan, Muzamil Khawaja, Noah Newman, Johao Escobar, Hafeez Ul Hassan Virk, Mahboob Alam, Fu'ad Al-Azzam, Celina M Yong, Hani Jneid","doi":"10.1007/s11886-024-02090-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The optimal revascularization strategy for coronary artery disease depends on various factors, such as disease complexity, patient characteristics, and preferences. Including a heart team in complex cases is crucial to ensure optimal outcomes. Decision-making between percutaneous coronary intervention and coronary artery bypass grafting must consider each patient's clinical profile and coronary anatomy. While current practice guidelines offer some insight into the optimal revascularization approach for the various phenotypes of coronary artery disease, the evidence to support either strategy continues to evolve and grow. Given the large amount of contemporary data on revascularization, this review aims to comprehensively summarize the literature on coronary artery bypass grafting and percutaneous coronary intervention in patients across the spectrum of coronary artery disease phenotypes.</p><p><strong>Recent findings: </strong>Contemporary evidence suggests that for patients with triple vessel disease, coronary artery bypass grafting is preferred over percutaneous coronary intervention due to better long-term outcomes, including lower rates of death, myocardial infarction, and target vessel revascularization. Similarly, for patients with left main coronary artery disease, both percutaneous coronary intervention and coronary artery bypass grafting can be considered, as they have shown similar efficacy in terms of major adverse cardiac events, but there may be a slightly higher risk of death with percutaneous coronary intervention. For proximal left anterior descending artery disease, both percutaneous coronary intervention and coronary artery bypass grafting are viable options, but coronary artery bypass grafting has shown lower rates of repeat revascularization and better relief from angina. The Synergy Between PCI with Taxus and Cardiac Surgery score can help in decision-making by predicting the risk of adverse events and guiding the choice between percutaneous coronary intervention and coronary artery bypass grafting. European and American guidelines both agree with including a heart team that can develop and lay out individualized, optimal treatment options with respect for patient preferences. The debate between coronary artery bypass grafting versus percutaneous coronary intervention in multiple different scenarios will continue to develop as technology and techniques improve for both procedures. Risk factors, pre, peri, and post-procedural complications involved in both revascularization strategies will continue to be mitigated to optimize outcomes for those patients for which coronary artery bypass grafting or percutaneous coronary intervention provide ultimate benefit. Methods to avoid unnecessary revascularization continue to develop as well as percutaneous technology that may allow patients to avoid surgical intervention when possible. With such changes, revascularization guidelines for specific patient populations may change in the coming years, which can serve as a limitation of this time-dated review.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02090-x","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: The optimal revascularization strategy for coronary artery disease depends on various factors, such as disease complexity, patient characteristics, and preferences. Including a heart team in complex cases is crucial to ensure optimal outcomes. Decision-making between percutaneous coronary intervention and coronary artery bypass grafting must consider each patient's clinical profile and coronary anatomy. While current practice guidelines offer some insight into the optimal revascularization approach for the various phenotypes of coronary artery disease, the evidence to support either strategy continues to evolve and grow. Given the large amount of contemporary data on revascularization, this review aims to comprehensively summarize the literature on coronary artery bypass grafting and percutaneous coronary intervention in patients across the spectrum of coronary artery disease phenotypes.

Recent findings: Contemporary evidence suggests that for patients with triple vessel disease, coronary artery bypass grafting is preferred over percutaneous coronary intervention due to better long-term outcomes, including lower rates of death, myocardial infarction, and target vessel revascularization. Similarly, for patients with left main coronary artery disease, both percutaneous coronary intervention and coronary artery bypass grafting can be considered, as they have shown similar efficacy in terms of major adverse cardiac events, but there may be a slightly higher risk of death with percutaneous coronary intervention. For proximal left anterior descending artery disease, both percutaneous coronary intervention and coronary artery bypass grafting are viable options, but coronary artery bypass grafting has shown lower rates of repeat revascularization and better relief from angina. The Synergy Between PCI with Taxus and Cardiac Surgery score can help in decision-making by predicting the risk of adverse events and guiding the choice between percutaneous coronary intervention and coronary artery bypass grafting. European and American guidelines both agree with including a heart team that can develop and lay out individualized, optimal treatment options with respect for patient preferences. The debate between coronary artery bypass grafting versus percutaneous coronary intervention in multiple different scenarios will continue to develop as technology and techniques improve for both procedures. Risk factors, pre, peri, and post-procedural complications involved in both revascularization strategies will continue to be mitigated to optimize outcomes for those patients for which coronary artery bypass grafting or percutaneous coronary intervention provide ultimate benefit. Methods to avoid unnecessary revascularization continue to develop as well as percutaneous technology that may allow patients to avoid surgical intervention when possible. With such changes, revascularization guidelines for specific patient populations may change in the coming years, which can serve as a limitation of this time-dated review.

Abstract Image

冠状动脉血管重建的现状:冠状动脉旁路移植手术与经皮冠状动脉介入治疗。
综述的目的:冠状动脉疾病的最佳血运重建策略取决于各种因素,如疾病复杂程度、患者特征和偏好。在复杂病例中加入心脏团队对于确保最佳治疗效果至关重要。在经皮冠状动脉介入治疗和冠状动脉旁路移植术之间做出决定时,必须考虑每位患者的临床特征和冠状动脉解剖结构。虽然目前的实践指南对冠状动脉疾病各种表型的最佳血管重建方法提供了一些见解,但支持这两种策略的证据仍在不断发展和增加。鉴于有关血管重建的当代数据量巨大,本综述旨在全面总结有关冠状动脉搭桥术和经皮冠状动脉介入治疗冠状动脉疾病表型患者的文献:当代证据表明,对于三血管疾病患者,冠状动脉旁路移植术优于经皮冠状动脉介入治疗,因为后者具有更好的长期疗效,包括较低的死亡率、心肌梗死率和靶血管再通率。同样,对于左主干冠状动脉疾病患者,经皮冠状动脉介入治疗和冠状动脉旁路移植术都可以考虑,因为就主要心脏不良事件而言,两者的疗效相似,但经皮冠状动脉介入治疗的死亡风险可能略高。对于近端左前降支动脉疾病,经皮冠状动脉介入治疗和冠状动脉旁路移植术都是可行的选择,但冠状动脉旁路移植术的重复血管再通率更低,心绞痛缓解效果更好。使用 Taxus 进行 PCI 和心脏手术之间的协同作用评分可以预测不良事件的风险,并指导在经皮冠状动脉介入治疗和冠状动脉旁路移植术之间做出选择,从而帮助做出决策。欧洲和美国的指南都同意包括一个心脏团队,该团队可以在尊重患者偏好的基础上制定并提出个性化的最佳治疗方案。随着冠状动脉旁路移植术和经皮冠状动脉介入治疗技术的不断改进,在多种不同情况下冠状动脉旁路移植术和经皮冠状动脉介入治疗之间的争论将继续发展。两种血管再通策略所涉及的风险因素、术前、术中和术后并发症将继续得到缓解,以优化那些接受冠状动脉旁路移植术或经皮冠状动脉介入治疗的患者的治疗效果,使其最终受益。避免不必要血管再通的方法在不断发展,经皮技术也在不断发展,使患者在可能的情况下避免手术干预。随着这些变化,针对特定患者群体的血管重建指南可能会在未来几年内发生变化,这也是本时间性综述的局限性所在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信